Abstract
Various health care bodies (regulatory, health technology assessment, academia, health care providers, scientific journals) request patient input in their decision-making processes. This represents a shift from disease-centered to patient-centered approaches to health care. What does this “patient centricity” mean for the pharmaceutical industry? A panel of senior pharmaceutical industry representatives discussed the following key issues: why the pharmaceutical industry needs to be part of the patient-centric movement; how the industry can become patient-centric; and what a patient-centric company actually does. We summarize the panel’s point of view on these key questions. The industry’s role has been to develop the science and medicines for prevention or treatment of disease. In response to changes in the current health care environment, the industry should focus its efforts on initiatives that will improve impact and value for patients and carers. True patient centricity requires a change in the industry’s cultural mindset, an increase in public trust, clearer roles and responsibilities within pharmaceutical organizations, openness to learn from others, and a framework to measure success. There are examples of industry engagement with patients throughout the drug discovery and development process. Patient-reported outcomes are becoming increasingly important endpoints in trials; they capture information of relevance to patients, identify preferences, and better inform treatment decision making. Understanding the patient experience can improve disease management at critical points in the disease course. The future of patient centricity lies in coordinated efforts by and alignment of multiple health care stakeholders, which can only be achieved through collaborations and consortia, with the industry playing a key role.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
PatientsLikeMe. https://www.patientslikeme.com. Accessed September 2016.
Engaged patients. http://engagedpatients.org. Accessed September 2016.
Muller B. Patient 3.0: The centre of drug development. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(suppl 1):62.
US Food and Drug Administration. Patient Engagement Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PatientEngagementAdvisoryCommittee. Accessed June 2016.
Perfetto EM, Burke L, Oehrlein EM, Epstein RS. Patient-focused drug development: a new direction for collaboration. Med Care. 2015;53:9–17.
European Medicines Agency (EMA). Incorporating patients’ views during evaluation of benefit-risk by the EMA Scientific Committees. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500173508.pdf. Accessed June 2016.
Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49:929–939.
British Medical Journal. Patient partnership: partnering with patients. http://www.bmj.com/campaign/patient-partnership. Accessed June 2016.
Berglas S, Jutai L, MacKean G, Weeks L. Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review. Res Involvement Engagement. 2016;2:21.
Mühlbacher AC. Patient-centric HTA: different strokes for different folks. Expert Rev Pharmacoecon Outcomes Res. 2015;15:591–597.
Deloitte. 2015 Global health care outlook: common goals, competing priorities. http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-global.pdf. Accessed August 2016.
Smith SK, Selig W, Harker M, et al. Patient engagement practices in clinical research among patient groups, industry, and academia in the United States: a survey. PLoS One. 2015;10:e0140232.
Sinek S. Start with why. https://www.startwithwhy.com. Accessed June 2016.
Getz KA. Establishing return-on-investment expectations for patient-centric initiatives. Ther Innov Regul Sci. 2015;49:745–749.
Critical Path Institute. Patient-Reported Outcome Consortium. https://c-path.org/programs/pro. Accessed September 2016.
GlaxoSmithKline. Data transparency. http://www.gsk.com/en-gb/behind-the-science/innovation/data-transparency. Accessed June 2016.
GlaxoSmithKline. Interactions with prescribers. http://www.gsk.com/en-gb/healthcare-professionals/interactions-with-prescribers. Accessed June 2016.
International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Patient Engagement in Research Working Group. http://www.ispor.org/sigs/patientcentered/pc_engagementinresearch.aspx. Accessed June 2016.
Medical Device Innovation Consortium (MDIC). Medical Device Innovation Consortium (MDIC) patient-centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. http://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Web.pdf. Accessed June 2016.
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Putting patients first: five global healthcare organizations sign Consensus Framework for Ethical Collaboration. http://www.ifpma.org/resource-centre/putting-patients-first-five-global-healthcare-organizations-sign-consensus-framework-for-ethical-collaboration. Accessed June 2016.
US Food and Drug Administration and European Medicines Agency Patient Engagement Cluster. http://www.fda.gov/forpatients/patientengagement/ucm507907.htm. Accessed December 2016.
New FDA/EMA rare diseases and patient engagement clusters underway. http://blogs.fda.gov/fdavoice/index.php/2016/10/new-fdaema-rare-diseases-and-patient-engagement-clusters-underway. Accessed December 2016.
National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed June 2016.
Health Technology Assessment international (HTAi) Interest Sub-Group for Patient/Citizen Involvement. Values and quality standards for patient involvement in HTA. http://www.htai.org/fileadmin/HTAi_Files/ISG/PatientInvolvement/v2_files/Info/PCISG-Info-PosterValuesandStandards-30-Jun14.pdf. Accessed June 2016.
Kleme J, Pohjanoksa-Mäntylä M, Airaksinen M, et al. Patient perspective in health technology assessment of pharmaceuticals in Finland. Int J Technol Assess Health Care. 2014;30:306–311.
European Patients’ Academy on Therapeutic Innovation (EUPATI). Patient involvement in the HTA decision making process. https://www.eupati.eu/health-technology-assessment/patient-involvement-in-the-hta-decision-making-process. Accessed June 2016.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Institute for Quality and Efficiency in Health care]. Involvement of people affected in the dossier assessment. https://www.iqwig.de/download/Involvement_of_people_affected_dossier_assessment.pdf. Accessed June 2016.
Fralick M. Putting patients first in the age of pharma. CMAJ. 2014;186:253.
Forsythe LP, Ellis LE, Edmundson L, et al. Patient and stakeholder engagement in the PCORI pilot projects: description and lessons learned. J Gen Intern Med. 2016;31:13–21.
EyeForPharma. Patient-centered culture by design. http://www.janssen.com/emea/sites/www_janssen_com_emea/files/2792_07jan16_pccultures_whitepaper_v13.pdf. Accessed June 2016.
Dewulf L. Patient engagement by pharma—why and how? A framework for compliant patient engagement. Ther Innov Regul Sci. 2015;49:9–16.
Hunter NL, O’Callaghan KM, Califf RM. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA. 2015;314:2499–2500.
Domecq JP, Prutsky G, Elraiyah T, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89.
Brett J, Staniszewska S, Mockford C, et al. Mapping the impact of patient and public involvement on health and social care research: a systematic review. Health Expect. 2014;17:637–650.
Clinical Trials Transformation Initiative. https://www.ctti-clinicaltrials.org. Accessed August 2016.
AstraZeneca. AstraZeneca and PatientsLikeMe announce global research collaboration. https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-patientslikeme-research-oncology-diabetes-lupus-respiratory-disease-13042015.html. Accessed June 2016.
GlaxoSmithKline. Engaging on patient engagement. http://gskmorethanmedicine.com/blog/2013/02/engaging-on-patient-engagement.html. Accessed June 2016.
US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labelling claims. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm193282.pdf. Accessed June 2016.
Patrick DL, Burke L. Focusing on the patient in drug development and research. ISPOR Connections. 2013;19:5–8.
Patient-Centered Outcomes Research Institute (PCORI). http://www.pcori.org. Accessed June 2016.
Wiering B, de Boer D, Delnoij D. Patient involvement in the development of patient-reported outcome measures: a scoping review. Health Expect.2017;20:11–23.
Banerjee AK, Okun S, Edwards IR, et al. Patient-reported outcome measures in safety event reporting: PROSPER Consortium guidance. Drug Saf. 2013;36:1129–1149.
Robbins DA, Curro FA, Fox CH. Defining patient-centricity: opportunities, challenges, and implications for clinical care and research. Ther Innov Regul Sci. 2013;47:349–355.
European Medicines Agency (EMA). Incorporating patients’ views during evaluation of benefit-risk by the EMA Scientific Committees. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500173508.pdf. Accessed June 2016.
National Institute for Health and Care Excellence (NICE). Hints and tips when preparing to be a patient expert. https://www.nice.org.uk/Media/Default/About/NICE-Communities/Public-involvement/Developing-NICE-guidance/Hints-Tips-Patient-Experts.pdf. Accessed June 2016.
European Patients’ Academy on Therapeutic Innovation (EUPATI). Expert training course for patients and patient representatives on the medicines research & development process. http://www.patientsacademy.eu/index.php/en/edu. Accessed June 2016.
O’Neill N, Mitchell G, Twycross A. The expert patient. Evid Based Nurs. 2016;19:41–42.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
du Plessis, D., Sake, JK., Halling, K. et al. Patient Centricity and Pharmaceutical Companies: Is It Feasible?. Ther Innov Regul Sci 51, 460–467 (2017). https://doi.org/10.1177/2168479017696268
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479017696268